As fast-growing biotech company Rainbow Coral Corp. (OTCBB: RBCC) works
to deliver new cutting-edge treatments in the field of regenerative
medicine, a major new breakthrough could soon lead to growing new lungs
for patients in a laboratory.
Researchers at Columbia University Medical Center (CUMC) recently
reported success in transforming human stem cells into functional lung
and airway cells. The startling advance could soon enable scientists to
model lung disease, screen drugs, study lung development and – someday –
generate lung tissue for transplant.
“For the first time, researchers can begin working on ways to use a
patient’s own skin cells to create functional lung tissue,” said RBCC
CEO Patrick Brown. “While incredible, this is only the latest
breakthrough in the booming field of stem-cell research and regenerative
medicine. The value of such advances, both in dollars and in
quality-of-life improvements, is just incalculable.”
In recent years, major discoveries in the usage of adult stem cells and
biologics have led to promising tech advances in the treatment of
once-incurable illnesses. Some analysts expect the market for
regenerative solutions to grow in value to more than $35 billion by 2019.
RBCC is working hard to capitalize on that growth by delivering new
solutions for the booming, global regenerative medicine market. The
company is currently in talks with a firm that could be on the verge of
a revolutionary advance in the way chronic back pain is treated. The
company has come up with a new procedure to address the discomfort
caused by Degenerative Disc Disease using an innovative, patentable
remedy derived from a patient’s own cells.
By acquiring or partnering with up-and-coming regenerative therapy
companies, RBCC plans to compete in the biotechnology industry alongside
NeoStem, Inc. (NYSE: NBS), Neuralstem, Inc. (NYSE: CUR), Smith & Nephew
(NYSE: SNN) and Pharmaceutical Product Development (NASDAQ: PPDI).
For more information on RBCC’s other biotech initiatives, please visit www.rainbowbiosciences.com.
About Rainbow Biosciences
Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral
Corp. (OTCBB: RBCC). The Company continually seeks out new partnerships
with biotechnology developers to deliver profitable new medical
technologies and innovations. For more information on our
growth-oriented business initiatives, please visit www.RainbowBioSciences.com.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act
of 1995: This news release contains forward-looking information within
the meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended,
including statements that include the words "believes," "expects,"
"anticipate" or similar expressions. Such forward-looking statements
involve known and unknown risks, uncertainties and other factors that
may cause the actual results, performance or achievements of the Company
to differ materially from those expressed or implied by such
forward-looking statements. In addition, description of anyone's past
success, either financial or strategic, is no guarantee of future
success. This news release speaks as of the date first set forth above
and the Company assumes no responsibility to update the information
included herein for events occurring after the date hereof.
Copyright Business Wire 2013